title: Intravitreal bevacizumab in myopic neovascular membranes: 24-month results.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: María I
authors.initials: MI
authors.lastname: López-Gálvez
authors.forename: Javier A
authors.initials: JA
authors.lastname: Montero Moreno
authors.forename: Jose C
authors.initials: JC
authors.lastname: Pastor Jimeno
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D047728:Myopia, Degenerative / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010778:Photochemotherapy; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab